Lidds

LIDDS develops effective pharmaceutical products for cancer and other diseases with the patented NanoZolid® technology. NanoZolid releases the medication locally and effectively which means significantly fewer side effects compared with systemic treatment allowing a controlled, sustained and customized release of medication for up to six months.

Visitingadress: Virdings allé 32b, Uppsala
SE-754 50, Sweden. +46 00 44 55 66 info@liddspharma.com

Financial Calendar

• 2019-02-28 Year End Report 2018 
• 2019-05-16 Quarterly Report January-March 2019
• 2019-05-16 Annual General Meeting
• 2019-08-29 Quarterly Report April-June 2019
• 2019-11-28 Quarterly Report July-September 2020-02-27 Year End Report 2019

Subscribe for news

Subscribe